iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Significant Transactions (Tables)

Significant Transactions (Tables) - RubrYc Therapeutics

12 Months Ended

Jun. 30, 2024

Asset Purchase Agreement

Summary of Purchase Price Allocation of Asset Acquisition


Intangible assets		$	1,228,000
Fixed assets			114,000
		$	1,342,000

Stock Purchase Agreement

Summary of Purchase Price Allocation of Asset Acquisition

The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:


Preferred stock		$	1,760,000
Intangible assets			4,300,000
Prepaid expenses			1,440,000
		$	7,500,000